IQP‐GC‐101 Reduces Body Weight and Body Fat Mass: A Randomized, Double‐Blind, Placebo‐Controlled Study
2014; Wiley; Volume: 28; Issue: 10 Linguagem: Inglês
10.1002/ptr.5158
ISSN1099-1573
AutoresPee‐Win Chong, Zhi‐Ming Beah, Barbara Grube, Linda Riede,
Tópico(s)Pharmacology and Obesity Treatment
ResumoIQP‐GC‐101 is a patented blend of the standardized extracts of Garcinia cambogia , Camellia sinensis , unroasted Coffea arabica , and Lagerstroemia speciosa . These individual ingredients of IQP‐GC‐101 have each shown promise in promoting weight loss; however, the efficacy of the blend has not been established. This randomized, placebo‐controlled, double‐blind, parallel group study conducted over 14 weeks (including a 2‐week run‐in phase) aimed to investigate the efficacy and safety of IQP‐GC‐101 in reducing body weight and body fat mass in overweight Caucasian adults. Subjects took three IQP‐GC‐101 or placebo tablets, twice a day, 30 min before main meals. All subjects also adhered to a 500 kcal/day energy deficit diet with 30% of energy from fat. Ninety‐one overweight and mildly obese subjects (46 in the IQP‐GC‐101 group, 45 in the placebo group) completed the study. After 12‐week intervention, IQP‐GC‐101 resulted in a mean (±SD) weight loss of 2.26 ± 2.37 kg compared with 0.56 ± 2.34 kg for placebo ( p U = 0 . 002 ). There was also significantly more reduction in body fat mass, waist circumference, and hip circumference in the IQP‐GC‐101 group. No serious adverse events were reported. The use of IQP‐GC‐101 has been shown to result in body weight and body fat reduction in the current study, with good tolerability. © 2014 InQpharm Group Sdn Bhd. Phytotherapy Research published by John Wiley & Sons, Ltd.
Referência(s)